Metabolic disruption impairs ribosomal protein levels, resulting in enhanced aminoglycoside tolerance
eLife · 2024
DOI: 10.7554/elife.94903 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Rauf Shiraliyev und 1 weiteren Autor:innen. Beteiligte Einrichtung: William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, United States. Hauptthemen laut MEDLINE: Ribosomal Proteins, Aminoglycosides, Anti-Bacterial Agents, Escherichia coli. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSF CAREER, NIAID NIH HHS, NIH/NIAID.
Abstract (Originalsprache)
Aminoglycoside antibiotics target ribosomes and are effective against a wide range of bacteria. Here, we demonstrated that knockout strains related to energy metabolism in Escherichia coli showed increased tolerance to aminoglycosides during the mid-exponential growth phase. Contrary to expectations, these mutations did not reduce the proton motive force or aminoglycoside uptake, as there were no significant changes in metabolic indicators or intracellular gentamicin levels between wild-type and mutant strains. Our comprehensive proteomics analysis unveiled a noteworthy upregulation of proteins linked to the tricarboxylic acid (TCA) cycle in the mutant strains during the mid-exponential growth phase, suggesting that these strains compensate for the perturbation in their energy metabolism by increasing TCA cycle activity to maintain their membrane potential and ATP levels. Furthermore, our pathway enrichment analysis shed light on local network clusters displaying downregulation across all mutant strains, which were associated with both large and small ribosomal binding proteins, ribosome biogenesis, translation factor activity, and the biosynthesis of ribonucleoside monophosphates. These findings offer a plausible explanation for the observed tolerance of aminoglycosides in the mutant strains. Altogether, this research provides valuable insights into the mechanisms of aminoglycoside tolerance, paving the way for novel strategies to combat such cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, United States.
ORCID-Profile: Rauf Shiraliyev, Mehmet A Orman
Förderung
- NSF CAREER
- NIAID NIH HHS
- NIH/NIAID
- National Institute of Allergy and Infectious Diseases
- National Science Foundation
Zitieren
APA
Shiraliyev, R., & Orman, M. A. (2024). Metabolic disruption impairs ribosomal protein levels, resulting in enhanced aminoglycoside tolerance. eLife. https://doi.org/10.7554/elife.94903
Vancouver
Shiraliyev R, Orman MA. Metabolic disruption impairs ribosomal protein levels, resulting in enhanced aminoglycoside tolerance. eLife. 2024. doi:10.7554/elife.94903
BibTeX
@article{Shiraliyev2024,
author = {Shiraliyev, Rauf and Orman, Mehmet A},
title = {Metabolic disruption impairs ribosomal protein levels, resulting in enhanced aminoglycoside tolerance},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.94903}
}
EUVIMED